Use of shingles vaccines significantly reduced disease burden
Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the burden of illness from shingles by 61.1% and the incidence of postherpetic neuralgia (PHN) by 66.5%.
Oxman, M.N., M.J. Levin, G.R. Johnson, K.E. Schmader, S.E. Straus, et al; for the Shingles Prevention Study Group. A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. NEJM. 2005; 352(22): 2271-84. http://www.nejm.org/doi/full/10.1056/NEJMoa051016